<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707222</url>
  </required_header>
  <id_info>
    <org_study_id>0277-19-ASF</org_study_id>
    <nct_id>NCT04707222</nct_id>
  </id_info>
  <brief_title>The Role of the Gut Microbiome in Modulating Physical Abilities in Humans</brief_title>
  <official_title>Assessing the Potential Role of the Gut Microbiome in Modulating Physical Abilities in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weizmann Institute of Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weizmann Institute of Science</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a growing body of evidence indicating the significant contribution of the gut&#xD;
      microbiome to host health and disease. Furthermore, it has been shown that exercise may&#xD;
      modify the microbiome composition. The diversity of athletes' gut microbiome was found higher&#xD;
      compared to gender and age-matched controls. However, important mechanistic questions related&#xD;
      to the possible associations between exercise and the human gut microbiome remain unanswered.&#xD;
&#xD;
      In this study, we propose to investigate using advanced state-of-the-art measurements of&#xD;
      physical activity level and related metabolic parameters whether there is a connection&#xD;
      between the microbiome and physical abilities in healthy participants and whether antibiotics&#xD;
      consumption can influence host physical abilities and glycemic responses through changes&#xD;
      induced in microbiome composition and function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During all days of the study, participants will be connected to a continuous glucose monitor&#xD;
      (CGM).&#xD;
&#xD;
      In the second segment of the study, participants will be randomized into two groups:&#xD;
      antibiotics or placebo, they will consume the pills for 7 days.&#xD;
&#xD;
      In the third segment, participants will undergo a Fecal Microbiota Transplant/placebo&#xD;
      administration. Subjects will be NPO at least 4 h before and for 1 hour following capsule&#xD;
      intake, to minimize the risk of vomiting during ingestion of capsules. In the event of&#xD;
      vomiting, patients will not be re-dosed. All patients will be evaluated after taking capsules&#xD;
      by the study investigators and observed for 15 minutes. Phone follow up and assessment using&#xD;
      open-ended questions and a standardized adverse event grading scale will take place 24-48hrs&#xD;
      after the administration.&#xD;
&#xD;
      Throughout the study, participants will collect stool and buccal samples which will be used&#xD;
      for microbiota profiling.&#xD;
&#xD;
      In study meetings, anthropometric measurements, medical history, GI symptoms questioner,&#xD;
      blood samples, urine samples, and Dual X-ray absorptiometry (DXA) will be taken. Participants&#xD;
      will also perform an extensive set of physical abilities test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Error while entering Principal investigator and sponsor. Was approved under another number&#xD;
    NCT05024188&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiome composition</measure>
    <time_frame>1 year</time_frame>
    <description>Stool, urine and oral samples will be sequenced and used for microbiota profiling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycemic response</measure>
    <time_frame>1 year</time_frame>
    <description>Continuous glucose monitoring (CGM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>1 year</time_frame>
    <description>&quot;System 4 â„¢&quot; BIODEX</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal aerobic capacity</measure>
    <time_frame>1 year</time_frame>
    <description>VO2max test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Physical Abilities</condition>
  <condition>Fecal Microbiota Transplant</condition>
  <arm_group>
    <arm_group_label>Antibiotics+FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 days of antibiotics- Ciprofloxacin, 500 mg 2/day &amp; Metronidazole (Flagyl), 500 mg 3/day.&#xD;
Fecal Microbiota Transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 days of cellulose placebo pills.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin &amp; Metronidazole</intervention_name>
    <description>Ciprofloxacin, 500 mg 2/day &amp; Metronidazole (Flagyl), 500 mg 3/day</description>
    <arm_group_label>Antibiotics+FMT</arm_group_label>
    <other_name>antibiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal microbiome transplant</intervention_name>
    <description>Fecal bacteriotherapy is the process of transferring stool from a healthy donor to another.</description>
    <arm_group_label>Antibiotics+FMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI&lt;28&#xD;
&#xD;
          -  Age - 20-35&#xD;
&#xD;
          -  Use to exercise in one or more of the following sports areas: running, swimming,&#xD;
             Zumba, dance or Aerobe class, football, basketball, functional training, volleyball,&#xD;
             surfing, tennis, wrestling athletics.&#xD;
&#xD;
          -  Exercise at least twice a week, for a minimum duration of 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consumption of antibiotics or probiotics 3 months prior to the first day of the&#xD;
             experiment.&#xD;
&#xD;
          -  Diagnosis of type 1 or type 2 diabetes.&#xD;
&#xD;
          -  Pregnancy, fertility treatments&#xD;
&#xD;
          -  Chronic disease (e.g. AIDS, Cushing syndrome, CKD, acromegaly, hyperthyroidism etc.)&#xD;
&#xD;
          -  Cancer and recent anticancer treatment&#xD;
&#xD;
          -  Psychiatric disorders&#xD;
&#xD;
          -  Coagulation disorders&#xD;
&#xD;
          -  IBD (inflammatory bowel diseases)&#xD;
&#xD;
          -  Bariatric surgery&#xD;
&#xD;
          -  Alcohol or substance abuse&#xD;
&#xD;
          -  BMI&gt;28&#xD;
&#xD;
          -  Any physical condition precluding the completion of a routine effort test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eran Elinav, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weizmann Institute of Science</affiliation>
  </overall_official>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weizmann Institute of Science</investigator_affiliation>
    <investigator_full_name>Eran Elinav</investigator_full_name>
    <investigator_title>Principal Investigator, Host-Microbiome Interaction Research Group</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

